JP2004534816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534816A5 JP2004534816A5 JP2003506898A JP2003506898A JP2004534816A5 JP 2004534816 A5 JP2004534816 A5 JP 2004534816A5 JP 2003506898 A JP2003506898 A JP 2003506898A JP 2003506898 A JP2003506898 A JP 2003506898A JP 2004534816 A5 JP2004534816 A5 JP 2004534816A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- chloro
- same
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 9
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- GTMLDEPLKLLIHD-UHFFFAOYSA-N 2-(5-chloro-2-ethyl-1h-indol-3-yl)-n,n-dimethylethanamine Chemical compound C1=C(Cl)C=C2C(CCN(C)C)=C(CC)NC2=C1 GTMLDEPLKLLIHD-UHFFFAOYSA-N 0.000 claims 1
- KSYMELKKLOFABL-UHFFFAOYSA-N 2-(5-chloro-2-methyl-1h-indol-3-yl)-n,n-dimethylethanamine Chemical compound C1=C(Cl)C=C2C(CCN(C)C)=C(C)NC2=C1 KSYMELKKLOFABL-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000000862 serotonergic effect Effects 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000356A ITRM20010356A1 (it) | 2001-06-21 | 2001-06-21 | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. |
| PCT/IT2002/000398 WO2003000252A1 (en) | 2001-06-21 | 2002-06-17 | 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010204733A Division JP2011016835A (ja) | 2001-06-21 | 2010-09-13 | ５−ｈｔ６および／または５−ｈｔ７セロトニン受容体のリガンドとして使用される５−ハロ−トリプタミン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004534816A JP2004534816A (ja) | 2004-11-18 |
| JP2004534816A5 true JP2004534816A5 (enExample) | 2010-11-18 |
| JP4683839B2 JP4683839B2 (ja) | 2011-05-18 |
Family
ID=11455609
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003506898A Expired - Fee Related JP4683839B2 (ja) | 2001-06-21 | 2002-06-17 | ５−ｈｔ６および／または５−ｈｔ７セロトニン受容体のリガンドとして使用される５−ハロ−トリプタミン誘導体 |
| JP2010204733A Pending JP2011016835A (ja) | 2001-06-21 | 2010-09-13 | ５−ｈｔ６および／または５−ｈｔ７セロトニン受容体のリガンドとして使用される５−ハロ−トリプタミン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010204733A Pending JP2011016835A (ja) | 2001-06-21 | 2010-09-13 | ５−ｈｔ６および／または５−ｈｔ７セロトニン受容体のリガンドとして使用される５−ハロ−トリプタミン誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7098233B2 (enExample) |
| EP (1) | EP1404317B1 (enExample) |
| JP (2) | JP4683839B2 (enExample) |
| KR (1) | KR100885308B1 (enExample) |
| CN (1) | CN100482223C (enExample) |
| AT (1) | ATE416767T1 (enExample) |
| AU (1) | AU2002317482B2 (enExample) |
| BR (1) | BR0210538A (enExample) |
| CA (1) | CA2455296C (enExample) |
| CY (1) | CY1108879T1 (enExample) |
| CZ (1) | CZ20033314A3 (enExample) |
| DE (1) | DE60230270D1 (enExample) |
| DK (1) | DK1404317T3 (enExample) |
| ES (1) | ES2319107T3 (enExample) |
| HU (1) | HUP0400250A3 (enExample) |
| IT (1) | ITRM20010356A1 (enExample) |
| MX (1) | MXPA03011510A (enExample) |
| PL (1) | PL367618A1 (enExample) |
| PT (1) | PT1404317E (enExample) |
| SK (1) | SK287828B6 (enExample) |
| WO (1) | WO2003000252A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04009318A (es) * | 2002-03-27 | 2005-01-25 | Glaxo Group Ltd | Derivados de quinolina y su uso como ligados 5-ht6. |
| JP4198733B2 (ja) | 2003-07-22 | 2008-12-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 関連性障害の予防および処置に有用な、５−ｈｔ２ａセロトニンレセプターのモジュレーターとしてのジアリールおよびアリールへテロアリールウレア誘導体 |
| US8086315B2 (en) | 2004-02-12 | 2011-12-27 | Asap Medical, Inc. | Cardiac stimulation apparatus and method for the control of hypertension |
| WO2005079845A1 (ja) | 2004-02-20 | 2005-09-01 | Astellas Pharma Inc. | 片頭痛予防薬 |
| US20080171788A1 (en) * | 2005-02-08 | 2008-07-17 | Shinobu Akuzawa | Medicament For Irritable Bowel Syndrome |
| KR20080044273A (ko) | 2005-08-08 | 2008-05-20 | 아스텔라스세이야쿠 가부시키가이샤 | 아실구아니딘 유도체 또는 그의 염 |
| WO2007046112A1 (en) * | 2005-10-19 | 2007-04-26 | Suven Life Sciences Inc. | Arylthioether tryptamine derivatives as functional 5-ht6 ligands |
| CN101384549B (zh) * | 2006-02-20 | 2011-04-13 | 安斯泰来制药株式会社 | 吡咯衍生物或其盐 |
| WO2008113818A1 (en) * | 2007-03-21 | 2008-09-25 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
| US20090093513A1 (en) * | 2007-10-09 | 2009-04-09 | Hamann Mark T | Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter |
| EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| CN107903173A (zh) * | 2011-08-05 | 2018-04-13 | 苏坎波公司 | 治疗精神分裂症的方法 |
| CN102816103B (zh) * | 2012-08-20 | 2014-05-07 | 冉瑞琼 | 硫化天冬氨酸修饰的退黑素衍生物及其应用 |
| US9008769B2 (en) | 2012-12-21 | 2015-04-14 | Backbeat Medical, Inc. | Methods and systems for lowering blood pressure through reduction of ventricle filling |
| US9370662B2 (en) | 2013-12-19 | 2016-06-21 | Backbeat Medical, Inc. | Methods and systems for controlling blood pressure by controlling atrial pressure |
| CN104529865B (zh) * | 2014-12-12 | 2017-02-01 | 广东东阳光药业有限公司 | 苄胺类衍生物及其在药物上的应用 |
| WO2016201373A1 (en) | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| HK1247555A1 (zh) | 2015-07-15 | 2018-09-28 | Axovant Sciences Gmbh | 用於预防和治疗与神经变性疾病相关的幻觉的作为5-ht2a血清素受体的调节剂的二芳基脲和芳基杂芳基脲衍生物 |
| US10342982B2 (en) | 2015-09-11 | 2019-07-09 | Backbeat Medical, Inc. | Methods and systems for treating cardiac malfunction |
| US10485658B2 (en) | 2016-04-22 | 2019-11-26 | Backbeat Medical, Inc. | Methods and systems for controlling blood pressure |
| CN108926565A (zh) * | 2017-05-26 | 2018-12-04 | 中国科学院上海生命科学研究院 | 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用 |
| EP3813810A4 (en) * | 2018-06-21 | 2022-03-30 | Robert John Petcavich | PROCESS FOR INDUCING DENDRITIC AND SYNAPTIC GENESIS IN CHRONIC NEURODEGENERATIVE DISEASES |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| BR112022016382A2 (pt) * | 2020-02-18 | 2022-10-25 | Gilgamesh Pharmaceuticals Inc | Triptaminas específicas para o uso no tratamento de doenças do humor |
| CA3182156A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| MX2022014605A (es) | 2020-05-19 | 2022-12-16 | Cybin Irl Ltd | Derivados de triptamina deuterada y metodos de uso. |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US20230346811A1 (en) * | 2020-09-18 | 2023-11-02 | Mydecine Innovations Group Inc. | Novel Formulations of Psilocybin And Psilocin Compounds as Serotonin Agonists in Combination With 3,4 Methylenedioxymethamphetamine (MDMA) |
| WO2022251351A1 (en) | 2021-05-25 | 2022-12-01 | ATAI Life Sciences AG | New n,n-dimethyltryptamine salts and crystalline salt forms |
| MX2023014620A (es) | 2021-06-09 | 2024-01-30 | Atai Therapeutics Inc | Nuevos profarmacos y conjugados de dimetiltriptamina. |
| WO2023018480A1 (en) * | 2021-08-09 | 2023-02-16 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Selective psychedelic compounds |
| WO2023129956A2 (en) * | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| CN114573578B (zh) * | 2022-02-16 | 2023-11-17 | 烟台宁远药业有限公司 | 一种烷基取代氮杂吲哚的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2825734A (en) * | 1955-04-11 | 1958-03-04 | Upjohn Co | Reduction of carbonylic radicals in indolyl-3 compounds |
| GB966562A (en) * | 1961-04-06 | 1964-08-12 | Parke Davis & Co | Amine compounds and means of producing the same |
| FR2315277A1 (fr) * | 1975-06-25 | 1977-01-21 | Anvar | Nouveaux derives pentacycliques, leur preparation et les compositions qui les contiennent |
| US4428877A (en) * | 1978-07-12 | 1984-01-31 | Richter Gedeon Vegyeszeti Gyar Rt. | Cis-10-bromo-E-homoeburnanes |
| GB8531612D0 (en) * | 1985-12-23 | 1986-02-05 | Beecham Wuelfing Gmbh & Co Kg | Compounds |
| US5300645A (en) * | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
| FR2712591B1 (fr) * | 1993-11-19 | 1996-02-09 | Pf Medicament | Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique. |
| US5688807A (en) * | 1994-03-11 | 1997-11-18 | Eli Lilly And Company | Method for treating 5HT2B receptor related conditions |
| US5504101A (en) * | 1994-05-06 | 1996-04-02 | Allelix Biopharmaceuticals, Inc. | 5-HT-1D receptor ligands |
| ATE296801T1 (de) | 1996-06-28 | 2005-06-15 | Meiji Seika Kaisha | Tetrahydrobezindol derivate |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| US6251893B1 (en) * | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
| DK1149078T3 (da) * | 1998-12-11 | 2006-07-10 | Univ Virginia Commonwealth | Selektive 5-HT6-receptorligander |
| US6403808B1 (en) * | 1999-12-10 | 2002-06-11 | Virginia Commonwealth University | Selective 5-HT6 receptor ligands |
| WO2000063203A1 (en) * | 1999-04-21 | 2000-10-26 | Allelix Biopharmaceuticals Inc. | Piperidine-indole compounds having 5-ht6 affinity |
| MXPA02001473A (es) * | 1999-08-12 | 2003-07-21 | Nps Allelix Corp | Azaindoles que tienen afinidad con el receptor de serotonina. |
| WO2004041781A1 (en) * | 2002-11-07 | 2004-05-21 | Suven Life Sciences Limited | Preparation of 3-aminoalkyl-substituted indole derivatives from phenylhydrazines and aminoketones |
-
2001
- 2001-06-21 IT IT2001RM000356A patent/ITRM20010356A1/it unknown
-
2002
- 2002-06-17 PL PL02367618A patent/PL367618A1/xx not_active IP Right Cessation
- 2002-06-17 CZ CZ20033314A patent/CZ20033314A3/cs unknown
- 2002-06-17 WO PCT/IT2002/000398 patent/WO2003000252A1/en not_active Ceased
- 2002-06-17 JP JP2003506898A patent/JP4683839B2/ja not_active Expired - Fee Related
- 2002-06-17 BR BR0210538-1A patent/BR0210538A/pt not_active Application Discontinuation
- 2002-06-17 DK DK02745793T patent/DK1404317T3/da active
- 2002-06-17 KR KR1020037016564A patent/KR100885308B1/ko not_active Expired - Fee Related
- 2002-06-17 CN CNB02814337XA patent/CN100482223C/zh not_active Expired - Fee Related
- 2002-06-17 HU HU0400250A patent/HUP0400250A3/hu unknown
- 2002-06-17 PT PT02745793T patent/PT1404317E/pt unknown
- 2002-06-17 AU AU2002317482A patent/AU2002317482B2/en not_active Ceased
- 2002-06-17 EP EP02745793A patent/EP1404317B1/en not_active Expired - Lifetime
- 2002-06-17 SK SK38-2004A patent/SK287828B6/sk not_active IP Right Cessation
- 2002-06-17 MX MXPA03011510A patent/MXPA03011510A/es active IP Right Grant
- 2002-06-17 AT AT02745793T patent/ATE416767T1/de active
- 2002-06-17 ES ES02745793T patent/ES2319107T3/es not_active Expired - Lifetime
- 2002-06-17 DE DE60230270T patent/DE60230270D1/de not_active Expired - Lifetime
- 2002-06-17 US US10/481,433 patent/US7098233B2/en not_active Expired - Fee Related
- 2002-06-17 CA CA2455296A patent/CA2455296C/en not_active Expired - Fee Related
-
2009
- 2009-03-06 CY CY20091100260T patent/CY1108879T1/el unknown
-
2010
- 2010-09-13 JP JP2010204733A patent/JP2011016835A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004534816A5 (enExample) | ||
| CA2455296A1 (en) | 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors | |
| JP2020183410A5 (enExample) | ||
| AU2019213454A1 (en) | 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto | |
| YU96502A (sh) | Derivati benzotiazola | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| JP2010514829A5 (enExample) | ||
| SE0104340D0 (sv) | New compounds | |
| JP2007508360A5 (enExample) | ||
| JP2004534850A5 (enExample) | ||
| EP1740581A4 (en) | ALSHEETS INHIBITORS SUITABLE FOR THE TREATMENT OF ALZHEIMER DISEASE: 2,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS | |
| EA016687B8 (ru) | Производные циклопропиламида | |
| EP1740559A4 (en) | ALSHEETS INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE SUITABLE 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS | |
| JP2018537535A5 (enExample) | ||
| JP2011505356A5 (enExample) | ||
| JP2005508872A5 (enExample) | ||
| JP2016522254A5 (enExample) | ||
| JP2004502755A5 (enExample) | ||
| EP1807396A4 (en) | 2-AMINOPYRIDINE COMPOSITIONS AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| DE60221283D1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| JP2004527492A5 (enExample) | ||
| EP1910321A4 (en) | NEW COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, INTERMEDIATE PRODUCTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6-MEDIATED ILLNESSES SUCH AS ALZHEIMER'S DISEASE, COGNITIVE ILLUSTRATIONS, SCHOISOPHRENIC ASSOCIATED COGNITIVE DISORDERS, OBESITAS AND PARKINSON DISEASE | |
| TW200612937A (en) | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide | |
| JP2015536965A5 (enExample) | ||
| CN103228618A (zh) | 新化合物及其医药用途 |